An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH.
A past study, MK-7962-024 (LIGHTRAY) (NCT06664801), learned about the safety and effects of sotatercept in people with PAH. One of the goals of that study was to learn about sotatercept when given at a dose (amount) based on the weight range a person is in (weight-banded doses) compared to when given based on a person's exact weight.
This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of sotatercept and if people tolerate it over a longer period of time.
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has current exposure or is planning to begin treatment with an activin signaling inhibitor (other than sotatercept)
Aurora, Colorado 80045, United States
Albuquerque, New Mexico 87131, United States
Mar del Plata, Buenos Aires B7600FZO, Argentina
Szeged, Csongrád megye 6725, Hungary
Budapest, Pest County 1083, Hungary
Budapest, Pest County 1096, Hungary
Bologna, 40139, Italy
Bunkyo, Tokyo 113-8655, Japan
Singapore, Central Singapore 119074, Singapore
Bangkoknoi, Bangkok 10700, Thailand
Muang, Chiang Mai 50200, Thailand